Drug intelligence / Profile preview

Cavistat

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral, Topical

Overview

Cavistat is an arginine bicarbonate calcium carbonate complex developed for the prevention and inhibition of dental caries. It has been clinically evaluated in sugarless mint confections and dentifrices, demonstrating its ability to reduce caries development and progression in children.

Brand names: BasicMints
Other names: arginine bicarbonate calcium carbonate complex

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on Cavistat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cavistat.

Explore the full profile